Alnylam Presents Final Phase I Data on First-Generation Amyloidosis Drug | GenomeWeb

Alnylam Pharmaceuticals this week released final data from a phase I study of its TTR-mediated amyloidosis drug ALN-TTR01, which showed the compound triggered dose-dependent and durable reductions in target protein levels.

ALN-TTR01 comprises siRNAs against transthyretin, or TTR. Alnylam previously stated that it intends to advance a different version of the drug called ALN-TTR02, which uses a second-generation lipid delivery vehicle and is in phase I testing, to the market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.